Open Access

Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI

  • Authors:
    • Hio Teng Cheong
    • Fei Xu
    • Chi Tung Choy
    • Connie Wun Chun Hui
    • Tony Shu Kam Mok
    • Chi Hang Wong
  • View Affiliations

  • Published online on: November 9, 2017     https://doi.org/10.3892/ol.2017.7377
  • Pages:901-907
  • Copyright: © Cheong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

Lung cancer has the highest incidence and mortality rate worldwide among all malignancy‑associated mortalities, of which non‑small cell lung cancer accounts for 80% of all cases. Resistance against epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) develops following 8‑12 months of disease progression, and is a critical issue. HCC827 cell lines with resistance to EGFR‑TKIs were successfully screened. The half maximal inhibitory concentration values were 1,000‑fold higher than the values for the parental HCC827 cell line, thereby demonstrating cross‑resistance against the same family of TKIs. The expression of B‑cell lymphoma 2 (Bcl2) was markedly increased in the resistant clones, as well as in the patient biopsies. The phosphatase and tensin homolog phosphoinositide 3‑kinase signaling axis is a potential mechanism for acquiring resistance, and therefore targeting Bcl2 may be a useful strategy for further investigations.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Cheong, H., Xu, F., Choy, C., Hui, C., Mok, T., & Wong, C. (2018). Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI. Oncology Letters, 15, 901-907. https://doi.org/10.3892/ol.2017.7377
MLA
Cheong, H., Xu, F., Choy, C., Hui, C., Mok, T., Wong, C."Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI". Oncology Letters 15.1 (2018): 901-907.
Chicago
Cheong, H., Xu, F., Choy, C., Hui, C., Mok, T., Wong, C."Upregulation of Bcl2 in NSCLC with acquired resistance to EGFR‑TKI". Oncology Letters 15, no. 1 (2018): 901-907. https://doi.org/10.3892/ol.2017.7377